From GlobeNewswire: 2025-02-07 08:50:00

AIM ImmunoTech Inc. announced plans to advance Ampligen as a vaccine adjuvant for avian influenza. The Company engaged Amarex Clinical Research for a follow-up IND application to study Ampligen in combination with AstraZeneca’s FluMist. Previous UAB research showed Ampligen increased immune response to seasonal variants and induced cross-reactive antibodies against avian influenza strains. AIM believes this combination therapy could be an effective barrier against avian flu infections. Pre-clinical work also showed Ampligen’s potential to provide cross-protective immunity against H5N1. AIM is moving forward with a second Ampligen and FluMist study in humans due to the growing threat of avian influenza.



Read more at GlobeNewswire: AIM ImmunoTech announces a planned follow-up clinical study